热疗联合静脉化疗治疗晚期卵巢癌的效果及安全性的Meta分析(1)
[摘要] 目的 系统评价热疗联合静脉化疗治疗卵巢癌的有效性和安全性。 方法 计算机检索PubMed、Cochrane library、EMbase、中國学术期刊全文数据库、中国生物医学文献数据库等，搜索年限从建库到2017年6月22日。纳入热疗联合静脉化疗治疗卵巢癌效果与安全性方面的随机对照研究。使用Cochrane手册5.1.0版的质量评价标准对纳入研究进行质量评价，使用RevMan 5.1.0版软件进行数据分析。结果 最终纳入20项研究，共1275例患者。Meta分析结果显示：与对照组比较，治疗组有效率[RR = 1.58，95%CI：1.42～1.77，P < 0.00 001]，腹水有效率[RR = 1.63，95%CI：1.32～2.02，P < 0.00 001]，CA125有效率[RR = 1.33，95%CI：1.14～1.55，P = 0.0003]，生活质量改善率[RR = 1.60，95%CI：1.24～2.06，P = 0.0003]均提高。热疗联合静脉化疗并不增加骨髓抑制、恶心呕吐、肝肾损害等的发生率(P > 0.05)。 结论 热疗联合静脉化疗可提高卵巢癌的疗效，改善生活质量，且不增加毒副作用。
[关键词] 静脉化疗；热疗；卵巢癌；系统评价
[中图分类号] R737.31 [文献标识码] A [文章编号] 1673-7210(2017)12(b)-0086-07
[Abstract] Objective To evaluate the effectiveness and safety of hyperthermia combined with intravenous chemotherapy for ovarian cancer. Methods The databases of PubMed， Cochrane library， EMbase， China national knowledge internet， the Chinese biomedical literature database were searched from building to June 22， 2017. Randomized controlled studies on the efficacy and safety of hyperthermia combined with intravenous chemotherapy in the treatment of ovarian cancer were included， the quality of the included studies was evaluated using the quality evaluation criteria of the Cochrane Handbook version 5.1.0， and the Review Manager 5.1.0 software was used for data analysis. Results Twenty studies including 1275 cases of ovarian cancer were included. The results of the Meta-analysis exhibited that compared with intravenous chemotherapy alone， hyperthermia combined with intravenous chemotherapy could increase effective rate [RR = 1.58， 95%CI： 1.42-1.77， P < 0.00 001]， effective rate of ascites[RR = 1.63， 95%CI： 1.32-2.02， P < 0.00 001]， effective rate of CA125 [RR = 1.33， 95%CI： 1.14-1.55， P = 0.0003]， the improvement rate of life quality [RR = 1.60， 95%CI： 1.24-2.06， P = 0.0003].Meanwhile， hyperthermia combined with intravenous chemotherapy did not significantly increase the incidence of myelosuppression， nausea and vomiting and liver and kidney dysfunction (P > 0.05). Conclusion Hyperthermia combined with intravenous chemotherapy may be more effective for ovarian cancer， improve life quality whereas adverse reactions are similar.
[Key words] Intravenous chemotherapy； Hyperthermia； Ovarian cancer； Meta-analysis
卵巢癌是妇科三大恶性肿瘤之一，其发病率呈逐年上升趋势，且随年龄增加而增加[1-2]，其死亡率居女性恶性肿瘤的首位[3]。因此，如何提高患者的治疗效果是临床亟待解决的问题。热疗是一种新的抗肿瘤治疗手段，使肿瘤局部温度升高，导致癌细胞凋亡。研究表明，热疗联合化疗可以提高卵巢癌的疗效，且不增加毒副作用，有良好的应用前景。现阶段已有较多的热疗联合化疗治疗卵巢癌的报道，但疗效尚无定论。本研究旨在系统评价热疗联合静脉化疗治疗卵巢癌的疗效及安全性，以期为其临床应用提供疗效及安全性方面的循证依据。, http://www.100md.com(陈达展 徐细明 周成)
[关键词] 静脉化疗；热疗；卵巢癌；系统评价
[中图分类号] R737.31 [文献标识码] A [文章编号] 1673-7210(2017)12(b)-0086-07
[Abstract] Objective To evaluate the effectiveness and safety of hyperthermia combined with intravenous chemotherapy for ovarian cancer. Methods The databases of PubMed， Cochrane library， EMbase， China national knowledge internet， the Chinese biomedical literature database were searched from building to June 22， 2017. Randomized controlled studies on the efficacy and safety of hyperthermia combined with intravenous chemotherapy in the treatment of ovarian cancer were included， the quality of the included studies was evaluated using the quality evaluation criteria of the Cochrane Handbook version 5.1.0， and the Review Manager 5.1.0 software was used for data analysis. Results Twenty studies including 1275 cases of ovarian cancer were included. The results of the Meta-analysis exhibited that compared with intravenous chemotherapy alone， hyperthermia combined with intravenous chemotherapy could increase effective rate [RR = 1.58， 95%CI： 1.42-1.77， P < 0.00 001]， effective rate of ascites[RR = 1.63， 95%CI： 1.32-2.02， P < 0.00 001]， effective rate of CA125 [RR = 1.33， 95%CI： 1.14-1.55， P = 0.0003]， the improvement rate of life quality [RR = 1.60， 95%CI： 1.24-2.06， P = 0.0003].Meanwhile， hyperthermia combined with intravenous chemotherapy did not significantly increase the incidence of myelosuppression， nausea and vomiting and liver and kidney dysfunction (P > 0.05). Conclusion Hyperthermia combined with intravenous chemotherapy may be more effective for ovarian cancer， improve life quality whereas adverse reactions are similar.
[Key words] Intravenous chemotherapy； Hyperthermia； Ovarian cancer； Meta-analysis
卵巢癌是妇科三大恶性肿瘤之一，其发病率呈逐年上升趋势，且随年龄增加而增加[1-2]，其死亡率居女性恶性肿瘤的首位[3]。因此，如何提高患者的治疗效果是临床亟待解决的问题。热疗是一种新的抗肿瘤治疗手段，使肿瘤局部温度升高，导致癌细胞凋亡。研究表明，热疗联合化疗可以提高卵巢癌的疗效，且不增加毒副作用，有良好的应用前景。现阶段已有较多的热疗联合化疗治疗卵巢癌的报道，但疗效尚无定论。本研究旨在系统评价热疗联合静脉化疗治疗卵巢癌的疗效及安全性，以期为其临床应用提供疗效及安全性方面的循证依据。, http://www.100md.com(陈达展 徐细明 周成)